ChemicalBook > Product Catalog >Organic Chemistry >Ketones >(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone

(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone

(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone Suppliers list
Company Name: Changzhou Huihan Biotechnology Co., Ltd.  Gold
Tel: 15380463325 15380463325
Email: 819573646@qq.com
Company Name: Heading (Nanjing)Pharmtechnologies Co., Ltd.  Gold
Tel: 025-58467899-832 13382406280
Email: liucheng@headingpharm.com
Company Name: Changzhou jinhan pharmaceutical technology co., LTD  Gold
Tel: 13917833665
Email: lyg@world-goldpharma.com
Company Name: SHANGHAI INSPO CHEMICAL CO.,LTD  Gold
Tel: 18917565227
Email: inspo@inspochem.com
Company Name: Hubei Peien Biotechnology Co., Ltd.  Gold
Tel: 13127581762 13127581762
Email: peilingchem@sina.com

(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone manufacturers

(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone Basic information
Product Name:(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone
Synonyms:(4S)-4-Phenyl-3-[5-(4-fluorophenyl)-5-oxopentanoyl]-1,3-oxazolidin-2-one;(S)-3-[5-(4-Fluorophenyl)-1,5-dioxopentyl]-4-phenyloxazolidin-2-one;1-(4-Fluorophenyl)-5-[(4S)-2-oxo-4-phenyl-3-oxazolidinyl]-1,5-pentanedione;3-[5-(4-fluorophenyl)-1, 5-dioxopentyl]-4-phenyl-(4S)-2-Oxazolidinone (FHO2);Ezetimibe Impurity 41;ETMB-04;(S)-1-(4-fluorophenyl)-5-(2-oxo-4-phenyloxazolidin-3-yl);1-(4-fluorophenyl)-5-[(4S)-2-oxo-4-phenyl-1,3-oxazolidin-3-yl]pentane-1,5-dione
CAS:189028-93-1
MF:C20H18FNO4
MW:355.36
EINECS:606-164-5
Product Categories:Intermediate of ezetimibe;pharmaceutical;Ezetimibe intermediates;Aromatics
Mol File:189028-93-1.mol
(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone Structure
(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone Chemical Properties
Melting point 90.0 to 94.0 °C
Boiling point 568.4±50.0 °C(Predicted)
density 1.288±0.06 g/cm3(Predicted)
storage temp. Sealed in dry,Room Temperature
solubility soluble in Acetone
form powder to crystal
pka-3.11±0.40(Predicted)
color White to Light yellow
Optical RotationConsistent with structure
InChIInChI=1S/C20H18FNO4/c21-16-11-9-15(10-12-16)18(23)7-4-8-19(24)22-17(13-26-20(22)25)14-5-2-1-3-6-14/h1-3,5-6,9-12,17H,4,7-8,13H2/t17-/m1/s1
InChIKeyXXSSRSVXDNUAQX-QGZVFWFLSA-N
SMILESC(C1=CC=C(F)C=C1)(=O)CCCC(N1[C@@H](C2=CC=CC=C2)COC1=O)=O
CAS DataBase Reference189028-93-1(CAS DataBase Reference)
Safety Information
HS Code 2934.99.4400
MSDS Information
(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone Usage And Synthesis
Chemical PropertiesOff-White Solid
Uses3-[5-(1,5-Dioxo-5-(p-fluophenylpentyl]-4(S)-phenyl-2-oxazolidinone (cas# 189028-93-1) is a compound useful in organic synthesis.
Application(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone is a core chiral building block in the synthetic route of ezetimibe. Ezetimibe reduces blood cholesterol by inhibiting intestinal cholesterol absorption and is commonly used for the treatment of primary hypercholesterolemia and other related conditions. This intermediate is used to construct the key carbon chain and chiral center of the drug molecule. Through subsequent reactions such as condensation, reduction and cyclization, key groups including fluorophenyl and oxazolidinone are introduced, and finally the core structure of ezetimibe is formed via ring closure.
Synthesis
(S)-(+)-4-Phenyl-2-oxazolidinone

99395-88-7

4-(4-Fluorobenzoyl)butyric acid

149437-76-3

(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone

189028-93-1

Example 1: Preparation of ezetimibe; (1-1) Preparation of (4S)-3-[5-(4-fluorophenyl)-1,5-dioxopentyl]-4-phenyl-2-oxazolidinone (Eq. 7); A reaction mixture was prepared by dissolving 200 g of 5-(4-fluorophenyl)-5-oxopentanoic acid (Eq. 8), 160 g of (S)-4-phenyl-oxazolidin-2-one (Eq. 9), and 11.6 g of 4- dimethylamino pyridine were dissolved in 600 mL of dichloromethane to prepare the reaction mixture. A solution prepared by dissolving 157 g of N,N'-dicyclohexylcarbimide in 200 mL of dichloromethane was added to the reaction mixture and stirred for 2 hours. Upon completion of the reaction, the resulting reaction mixture was filtered to remove the by-products. The filtrate was washed sequentially with 1 L of 6N HCl, 1 L of water and 1 L of saturated sodium chloride solution, dried with anhydrous magnesium sulfate, filtered and the solvent was removed by distillation under reduced pressure. The residue was dissolved in 2 L of methanol by heating and cooled to induce crystallization. 2L of water was added and stirred for 30 minutes. The solid was separated by filtration to give 289 g of (4S)-3-[5-(4-fluorophenyl)-1,5-dioxopentyl]-4-phenyl-2-oxazolidinone as a white solid (yield: 86%).1H NMR (300 MHz, CDCl3): δ 7.92 (2H, m), 7.35-7.13 (5H, m), 7.04 (2H, m). 5.43 (1H, q), 4.75 (1H, t), 4.22 (1H, q), 3.05-2.93 (4H, m), 2.03 (2H, m).

References[1] Patent: WO2010/71358, 2010, A2. Location in patent: Page/Page column 14-15
[2] Patent: WO2006/122216, 2006, A2. Location in patent: Page/Page column 41-42
[3] Synthetic Communications, 2016, vol. 46, # 20, p. 1687 - 1693
[4] Patent: CN106397292, 2017, A. Location in patent: Paragraph 0053; 0086; 0087
[5] Patent: CN104513187, 2017, B. Location in patent: Paragraph 0063; 0064; 0065; 0066
Tag:(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone(189028-93-1) Related Product Information
Ezetimibe Cyclopentanecarbaldehyde Oxadixyl Methyl (3R,4S)-1-(4-fluorophenyl)-2-oxo-4-[4-(phenylmethoxy)phenyl]-3-azetidinepropanoate (3R,4S)-1-(4-Fluorophenyl)-2-oxo-4-[4-(benzyloxy)phenyl]-3-azetidinepropanoic acid EZETIMIBE-D4 1,5-Pentanedione, 1-(3-fluorophenyl)-5-[(4S)-2-oxo-4-phenyl-3-oxazolidinyl]- Phenyl valerate tert-Amyl methyl ether Tetrapentylammonium bromide Phenyl resin 4-(4-Fluorobenzoyl)butyric acid 4-[[(4-Fluorophenyl)imino]methyl]-phenol (R)-3-((S)-5-(4-fluorophenyl)-5-hydroxypentanoyl)-4-phenyloxazolidin-2-one EzetiMibe (3R,4R,3'S)-IsoMer ent-EzetiMibe (4S)-3-[(5R)-5-(4-Fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one 5-(4-Fluorophenyl)valeric acid